Against 443 aerobic and anaerobic bacteria isolated from diabetic foot infections, ceftobiprole MICs (g/ml) at which 90% of the isolates tested were inhibited were as follows: methicillin-resistant Staphylococcus aureus, 1; methicillin-susceptible S. aureus and Staphylococcus lugdunensis, 0.5; Anaerococcus prevotii, 0.125; Finegoldia magna, 0.5; Peptoniphilus asaccharolyticus, 1; Peptostreptococcus anaerobius, 4; Escherichia coli and Enterobacter species, 0.125; Klebsiella species, 2; and Pseudomonas aeruginosa, 8.
Diabetic foot infections (DFIs) are common complications and account for ϳ20% of all hospitalizations for Ͼ18 million diabetics in the United States (1, 2) . Early-stage DFIs are generally due to Staphylococcus aureus, and 20% of hospitalized DFI patients grow methicillin-resistant S. aureus (MRSA) (7); more-advanced DFIs involve aerobic gram-negative rods, and 45% also involve anaerobes (4.1 to 5.8 bacterial species isolated per specimen, composed of 2.9 to 3.5 aerobes and 1.2 to 2.6 anaerobes) (6) Ceftobiprole (BAL 9141) is a new broad-spectrum pyrrolidinone cephem antimicrobial active against S. aureus bacteria, including MRSA and vancomycin-intermediate S. aureus, vancomycin-resistant Enterococcus faecalis (but not ampicillin-resistant enterococci), other gram-positive organisms, and many gram-negative rods except Proteus vulgaris or extended-spectrum beta-lactamase (ESBL)-producing strains of Enterobacteriaceae (3, 5, 8, 9, 15) , but data on its activity against anaerobes are limited (14) .
Consequently, we studied the activity of ceftobiprole against 443 aerobic and anaerobic strains isolated from pretreatment cultures (2001 to 2004) obtained after debridement from patients with symptomatic, complicated DFIs at 52 domestic clinical study sites and sent to our lab via overnight courier. All isolates (Table 1) were identified by standard criteria (10, 11) . Standard antimicrobial laboratory powders were supplied by the manufacturers and reconstituted accordingly.
Anaerobic susceptibility testing was performed by the agar dilution method according to CLSI standard M11-A6 (12) with a final inoculum of 10 5 CFU/spot. Plates were incubated at 37°C for 44 to 48 h in an anaerobic chamber (Anaerobe Systems, California). Aerobic isolates were subcultured onto Trypticase soy blood agar and tested by the broth microdilution method using cation-adjusted Mueller-Hinton broth, with lysed horse blood supplementation for streptococci and corynebacteria (4, 13) . The trays were prepared in-house with serial twofold dilutions of the drugs by using the Quick-Spense apparatus (Sally Spring Instrument Co. Inc., Germantown, MD) and stored at Ϫ70°C until use. Colonies were suspended from overnight growth and added to the trays for a final inoculum of approximately 5 ϫ 10 5 CFU/ml. The trays were incubated for 18 to 24 h and examined.
Results are presented in Table 1 . The ceftobiprole quality control strain MICs were as follows: S. aureus ATCC 29213, 0.25 g/ml, seven times; 0.5 g/ml, twice; Escherichia coli ATCC 25922, 0.03 g/ml, once; 0.06 g/ml, five times; Bacteroides fragilis ATCC 25285, 16 g/ml, four times; Bacteroides thetaiotaomicron ATCC 29741, 16 g/ml, twice; 32 g/ml, twice; Clostridium difficile ATCC 700057, 2 g/ml, once; 4 g/ml, once; 8 g/ml, once.
Ceftobiprole was the most consistently active of all the drugs tested against gram-positive organisms. Ceftobiprole inhibited all methicillin-susceptible S. aureus and Staphylococcus lugdunensis strains at Յ0.5 g/ml and had a MIC at which 90% of the isolates tested were inhibited (MIC 90 ) of 1 g/ml against MRSA and Staphylococcus epidermidis isolates, showing greater activity than linezolid (MIC 90 , 2 g/ml). Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Streptococcus pyogenes isolates were all susceptible to Յ0.015 g/ml of ceftobiprole. Ceftobiprole was active against corynebacteria at Յ0.125 g/ml except all five Corynebacterium jeikeium strains, along with 1/10 Corynebacterium striatum strains, two/six Corynebacterium tuberculostearicum strains, and one Corynebacterium urealyticum strain, which had MICs of Ͼ32 g/ml. Corynebacterium amycolatum strains showed a bimodal distribution with 11/15 isolates susceptible to Յ0.25 g/ml and 4/15 isolates having MICs of Ͼ32 g/ml.
Ceftobiprole was active against E. coli and Enterobacter species (MIC 90 for both, 0.125 g/ml) and Klebsiella species (MIC 90 , 2 g/ml). None of these isolates were ESBL producers. It was active against Proteus mirabilis at Յ0.125 g/ml, but (2) , Corynebacterium jeikeium (5), Corynebacterium striatum (10), Corynebacterium tuberculostearicum (6), Corynebacterium urealyticum (1), and Corynebacterium xerosis (2) . b S. dysgalactiae subsp. equisimilis (12) and S. pyogenes (3) . c Enterobacter aerogenes (4) and Enterobacter cloacae (11) . d Klebsiella oxytoca (9) and Klebsiella pneumoniae (6) . e Proteus mirabilis (8), P. vulgaris (4), and Providencia rettgeri (3) . f Bacteroides caccae (1), Bacteroides distasonis (1), Bacteroides ovatus (3), Bacteroides stercoris (2), Bacteroides theta (4), Bacteroides uniformis (3), and Bacteroides vulgatus (2) .
g Porphyromonas asaccharolytica (7) and Porphyromonas somerae (formerly Porphyromonas levii) (8) .
h Clostridium aminovalericum (1), Clostridium cadaveris (4), Clostridium clostridioforme (3), Clostridium innocuum (1), Clostridium malenomenatum (1), Clostridium perfringens (6), Clostridium sphenoides (1), and Clostridium subterminale (2) .
i Anaerococcus tetradius (7), Anaerococcus vaginalis (2), Peptostreptococcus micros (6) , and Peptoniphilus harei (2 Ceftobiprole was also active against gram-positive anaerobes. All Propionibacterium acnes strains were susceptible to Յ0.25 g/ml. Peptostreptococci and clostridia were susceptible to Յ1 g/ml except for Peptostreptooccus anaerobius (MIC 90 of 4 g/ml), one strain of Clostridium innocuum (MIC of 4 g/ ml), and one of three isolates of Clostridium clostridioforme (MIC of 8 g/ml). Finegoldia magna isolates were highly susceptible to ceftobiprole (MIC, Յ0.5 g/ml) and yet generally resistant to cefepime, ceftazidime, cefotaxime, and levofloxacin and had a cefoxitin MIC 90 of 2 g/ml.
All seven strains of Porphyromonas asaccharolytica, including a beta-lactamase-positive strain, and five of eight strains of Porphyromonas somerae were susceptible to Յ0.125 g/ml of ceftobiprole. Bacteroides fragilis and B. fragilis group species, many of which were resistant to cefoxitin, and Prevotella bivia and Prevotella melaninogenica strains were less susceptible to ceftobiprole.
Recent data have shown that the in vitro activity of an antimicrobial agent against an anaerobic species may vary depending on the site of isolation, such as an intra-abdominal infection versus a DFI (Citron et al., 45th ICAAC). Consequently, it is important to test isolates from single clinical sources to determine a drug's potential.
In our study, ceftobiprole was generally active against MRSA, Staphylococcus haemolyticus, S. lugdunensis, and group B streptococci, in accord with other studies (3, 8) . Hebeisen et al. (8) reported a MIC 90 of 8 g/ml against S. haemolyticus, while ours was 2 g/ml. We found that ceftobiprole was active against most corynebacteria at Յ0.125 g/ml but had species variability.
None of our E. coli or Klebsiella species isolates were ESBL producers. As reported previously (8) , Proteus mirabilis strains were susceptible to ceftobiprole while P. vulgaris strains were resistant. Issa et al. (9) reported a ceftobiprole MIC 90 of 8 g/ml against 30 strains of P. aeruginosa, while Hebeisen et al. (8) reported a MIC 90 of 16 g/ml against 60 ceftazidimesusceptible strains but a MIC 90 of Ͼ64 g/ml against 17 ceftazidime-resistant strains. All of our P. aeruginosa isolates were susceptible to Յ8 g/ml of ceftazidime and ceftobiprole, and their activities paralleled each other.
Like Wootton et al. (14), we also found B. fragilis and B. fragilis group species to be generally resistant to ceftobiprole, possibly due to chromosomal beta-lactamase activity of these strains. Unfortunately, they did not report on individual anaerobic species except B. fragilis and instead lumped them into broad groups; consequently, our data are not directly comparable. Propionibacterium acnes was susceptible to Յ0.25 g/ml of ceftobiprole. In contrast to the work of Wootton et al. (14) , who reported the ceftobiprole MIC 90 of 59 grouped grampositive anaerobic cocci as 32 g/ml, our study noted that peptostreptococci were susceptible to Յ1 g/ml except for Peptostreptococcus anaerobius, which had a MIC 90 of 4 g/ml. Similarly, Wootton et al. (14) studied 48 mixed species of clostridia and found a MIC 90 of 64 g/ml; however, in our study, most clostridia, such as Clostridium cadaveris, Clostridium perfringens, and Clostridium subterminale, were susceptible to Յ1 g/ml except for some isolates of C. clostridioforme and C. innocuum.
Ceftobiprole had good activity against a wide range of grampositive aerobes and anaerobes isolated from DFIs. Its activity against gram-negative aerobes and anaerobes was species dependent.
